The German Cancer Society, the Bundesverband Prostatakrebs Selbsthilfe e.V. (BPS), the Förderverein Hilfe bei Prostatakrebs (FHbP) and OnkoZert participate in the multinational study.
Berlin 02.02.2016. The German Cancer Society announces participation in a multinational study for improvement of quality of life for patients with localized prostate cancer. The project „Prostate Cancer Outcomes ‒ Compare and Reduce Variation“ is financed with 3 million Australian dollars by the Movemeber Foundation and envolves hospitals from 10 countries.
The study will gather and compare patient reported quality of life information and clinical endpoints utilizing identical units of measure for reporting by each of the participating hospitals. Indicators employed in the study are already mostly utilized in the Prostate Cancer Centers certified by the German Cancer Society and are recommended by the International Consortiumfor Health Outcomes Measurement (ICHOM). The German Cancer Society will be responsible for coordinating the 24 hospitals in Germany participating in the study. Further partners in this project are the BPS, FHbP and the independent institute OnkoZert.
25 percent newly diagnosed male cancer patients have prostate cancer. Prostate cancer is one of the most frequent cancers in men in Germany and in many other countries. Possible treatment complications are incontinence, bowel irritation, erectile dysfunction and psychological problems. Significant differences in treatment results worldwide are being suspected. Recording them in the participating hospitals and in a central data repository of the study aims to provide transparency and explanations of differences in treatment quality.
Günter Feick, BPS and Günther Carl, FHbP underline the importance of this project:
„Studies about the quality of treatments for prostate cancer are mostly recording mortality data. Knowledge about quality of life reported by patients is scarce. Furthermore there are no international comparisons on health outcomes based upon a sizeable amount of data reported by a larger number of hospitals. Both aspects are taken into account by the Movember study and that is why we are supporting the study. We are convinced – measuring and comparing leads to improvement of treatments.“
Dr. Johannes Bruns, secretary general of the German Cancer Society emphasizes, „There are various efforts currently under way for improving the treatment of prostate cancer in Germany. One of them is the extensive PREFERE study comparing the various treatment modalities for the locally confined prostate cancer. The new project is complementing existing attempts – it will be condusive for better identification of key factors important for high quality health outcomes in the treatment of prostate cancer. I am pleased that we are having this opportunity offered by Movember to participate in this project.“
Paul Villanti, Director of Programmes Movember Foundation addressing this collaboration:
“We’re pleased to announce that we are working with the German Cancer Society and partners on this new project which enables us to expand this work into Germany.
We’re committed to the implementation of a set of national and international prostate cancer outcomes projects to better measure treatment and quality of care results.
Looking at these results between countries will offer an unprecedented opportunity to dramatically reduce variation in care and better understand what’s best for men with prostate cancer”
The German Cancer Society
The German Cancer society – a successor organization of the „Comité für Krebssammelforschung“ founded 1900 – is the largest scientifc organization for oncology in the german speaking community. The German Cancer Society encompasses more than 7.400 individual members in 24 work groups dedicated to research and treatment of cancer in addition to 16 federal state cancer societies and 35 supporting members.
The German Cancer Society is actively supporting evidence based cancer care, interdisciplinarity, consequent standards of treatment quality and is co-initiator of the National Cancer Plan. For more information see: www.krebsgesellschaft.de
The Movember Foundation
The Movember Foundation is a global charity committed to the improvement of men`s health. Movember finances innovative research and living with cancer support programs aiming towards helping men living a happier, healthier and longer life. The work of the Movember Foundation is supported by millions of people helping to fund over 1.000 projects in the interest of patients with prostate cancer, testicular cancer, poor mental illness and physical inactivity. Movember`s vision ist to take action for creating positive change in men’s health by raising awareness and educating men year-round.
For more information see: www.movember.com
The Bundesverband Prostatakrebs Selbsthilfe e. V. (BPS)
The BPS is a charitable organization of and for prostate cancer patients and there next of kin
with 237 patient support groups across Germany. The BPS operates under the auspices of the charitable foundation Deutsche Krebshilfe and is a member of the European Prostate Cancer Patient Coalition Europa UOMO.
For more information see: www.prostatakrebs-bps
|The Förderverein Hilfe bei Prostatakrebs (FHbP
The charitable organization FHbP was founded by members of the Bundesverband Prostatakrebs Selbsthilfe e.V. on 3 July 2014 at Magdeburg, is registered and based in Bonn. The FHbP aims to foster prostate cancer research, support men with prostate cancer and the BPS and strives to build a charitable foundation.
For more information see: http://fhbp.de
OnkoZert is an independent institute.serving the certification system of the German Cancer Society for organ specific cancer centers and comprehensive centers.
For more information see www.onkozert.de
Pressestelle der Deutschen Krebsgesellschaft e. V.
Dr. Katrin Mugele
Tel: +49 30 3229329-60